Genetic association of five plasminogen activator inhibitor-1 (PAI-1) polymorphisms and idiopathic recurrent pregnancy loss in Korean women

Summary

Plasminogen activator inhibitor-1 (PAI-1) is important for maintaining pregnancy. Aberrantly increased PAI-1 levels may contribute to thrombosis and inflammation, leading to pregnancy loss. This study investigated the association of PAI-1 polymorphisms (PAI-1 rs2227631 [-844G>A], rs1799889 [-675 4G/5G], rs6092 [43G>A], rs2227694 [9785G>A], and rs7242 [11053T>G]) with idiopathic recurrent pregnancy loss (RPL) in Korean women. We screened 308 RPL patients and 227 control participants for five PAI-1 polymorphisms. Genotyping of PAI-1 was performed by polymerase chain reaction-restriction fragment length polymorphism assay. PAI-1 4G4G and -844AA/ 4G4G/11053GG genotypes were associated with RPL. PAI-1 -844A/4G/43G/9785G/11053G haplotype was connected to hypofibrinolytic status (i.e. increased levels of plasma PAI-1, increased numbers of platelets, reduced prothrombin time, and reduced activated partial thromboplastin time). Moreover, PAI-1 11053TG+GG frequency was positively related to plasma homocysteine and urate levels, whereas -844AA frequency was associated with plasma folate concentrations according to ordinal logistic regression analysis. Based on these results, we propose that PAI-1 -844G>A, 4G/5G, and 11053T>G polymorphisms are markers of RPL.

Keywords

Plasminogen activator inhibitor-1 - polymorphism - recurrent pregnancy loss

^* Young Joo Jeon and Young Ran Kim contributed equally to this work.

• References

• 1 Stephenson M, Kutteh W. Evaluation and management of recurrent early pregnancy loss. Clin Obstet Gynecol 2007; 50: 132-145.
• 2 Coulam CB, Clark DA, Beer AE. et al. Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1997; 38: 57-74.
• 3 Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2013; 99: 63.
• 4 Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010; 93: 1234-1243.
• 5 Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012; 98: 1103-1111.
• 6 Francis C, Marder V. Mechanisms of fibrinolysis. In:Williams Haematology. 5th ed. McGraw Hill; 1995. pp. 1252-1260.
• 7 Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995; 8: 277-290.
• 8 Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
• 9 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
• 10 Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 1999; 99: 2496-2498.
• 11 Sappino AP, Huarte J, Belin D. et al. Plasminogen activators in tissue remodeling and invasion: mRNA localisation in mouse ovaries and implanting embryos. J Cell Biol 1989; 109: 2471-2479.
• 12 Piquette GN, Simon C, el Danasouri I. et al. Gene regulation of interleukin-1 beta, interleukin-1 receptor type 1, and plasminogen activator inhibitor-1 and -2 in human granulosa-luteal cells. Fertil Steril 1994; 62: 760-770.
• 13 Hu ZY, Liu YX, Liu K. et al. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 1999; 194: 183-195.
• 14 Graham CH. Effect of transforming growth factor-beta on the plasminogen activator system in cultured first trimester human cytotrophoblasts. Placenta 1997; 18: 137-143.
• 15 Ma Z, Jhun B, Jung SY. et al. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol 2008; 121: 1006-1012.
• 16 Ma Z, Paek D, Oh CK. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Exp Allergy 2009; 39: 1136-1144.
• 17 Hultman K, Tjarnlund-Wolf A, Odeberg J. et al. Allele-specific transcription of the PAI-1 gene in human astrocytes. Thromb Haemost 2010; 104: 998-1008.
• 18 Su MT, Lin SH, Chen YC. et al. Genetic association studies of ACE and PAI-1 genes in women with recurrent pregnancy loss. A systematic review and meta-analysis. Thromb Haemost 2013; 109: 8-15.
• 19 Morange PE, Saut N, Alessi MC. et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007; 27: 2250-2257.
• 20 Barch MJ, Knutsen T, Spurbeck JL. The AGT Cytogenetics Laboratory Manual. 3rd ed. New York: Lippincott-Raven publishers; 1997. .
• 21 Jeon YJ, Choi YS, Rah HC. et al. The reduced folate carrier-1 (RFC1 696T>C) polymorphism is associated with spontaneously aborted embryos in Koreans. Genes Genom 2011; 33: 223-228.
• 22 Ritchie MD, Hahn LW, Roodi N. et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
• 23 Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002; 34: 88-95.
• 24 Lee SY, Chung Y, Elston RC. et al. Log-linear model-based multifactor dimensionality reduction method to detect gene gene interactions. Bioinformatics 2007; 23: 2589-2595.
• 25 Alturfan AA, Eralp L, Emekli N. Investigation of inflammatory and hemostatic parameters in female patients undergoing total knee arthroplasty surgery. Inflammation 2008; 31: 414-421.
• 26 Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Update 2011; 17: 803-812.
• 27 Buchholz T, Thaler CJ. Inherited thrombophilia: impact on human reproduction. Am J Reprod Immunol 2003; 50: 20-32.
• 28 Preston FE, Rosendaal FR, Walker ID. et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
• 29 Hickey M, Fraser IS. Clinical implications of disturbances of uterine vascular morphology and function. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 937-951.
• 30 Lockwood CJ. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualisation of human endometrial stromal cells. Am J Obstet Gynecol 2001; 184: 798-804.
• 31 Smith AN, Carter QL, Kniss DA. et al. Characterisation of a TGFbeta-responsive human trophoblast-derived cell line. Placenta 2001; 22: 425-431.
• 32 Chakraborty C, Gleeson LM, McKinnon T. et al. Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 2002; 80: 116-124.
• 33 Kappelmayer J, Bacskό G, Kelemen E. et al. Onset and distribution of factor XIII-containing cells in the mesenchyme of chorionic villi during early phase of human placentation. Placenta 1994; 15: 613-623.
• 34 Anwar R, Gallivan L, Edmonds SD. et al. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905.
• 35 Glueck CJ, Phillips H, Cameron D. et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000; 49: 845-852.
• 36 Maiello M, Torella M, Caserta L. et al. Hypercoagulability during pregnancy: evidences for a thrombophilic state. Minerva Ginecol 2006; 58: 417-422.
• 37 Harville EW, Viikari JS, Raitakari OT. Preconception cardiovascular risk factors and pregnancy outcome. Epidemiology 2011; 22: 724-730.
• 38 Bergen NE, Jaddoe VW, Timmermans S. et al. Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: the Generation R Study. Br J Obstet Gynecol 2012; 119: 739-751.
• 39 Akahori Y, Masuyama H, Hiramatsu Y. The correlation of maternal uric acid concentration with small-for-gestational-age fetuses in normotensive pregnant women. Gynecol Obstet Invest 2012; 73: 162-167.
• 40 Lyngdoh T, Marques-Vidal P, Paccaud F. et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One 2011; 6: e19901.
• 41 Nakashima A, Shima T, Inada K. et al. The balance of the immune system between T cells and NK cells in miscarriage. Am J Reprod Immunol 2012; 67: 304-310.
• 42 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-e91.
• 43 Di Minno MN, Tremoli E, Coppola A. et al. Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost 2010; 103: 942-961.
• 44 Akpek M, Kaya MG, Uyarel H. et al. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis 2011; 219: 334-341.
• 45 Vanizor Kural B, Orem A, Cimşit G. et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332: 23-30.
• 46 Tofler GH, D’Agostino RB, Jacques PF. et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost 2002; 88: 799-804.
• 47 Wei W, Liu SY, Zeng FF. et al. Meta-analysis of the association of the C677T polymorphism of the methylenetetrahydrofolate reductase gene with hyperuricemia. Ann Nutr Metab 2012; 60: 44-51.